PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Recurrent Glioblastoma Multiforme (GBM) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRT-3645’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRT-3645 is under development for the treatment of solid tumor including recurrent glioblastoma, melanoma, HER2-negative breast cancer, HER2 positive breast cancer, astrocytoma, malignant mesothelioma, HPV-negative HNSCC (including oral cavity, oropharynx, hypopharynx, and larynx), sarcoma, endometrial cancer, and non-small cell lung cancer. The drug candidate acts by targeting CDK4 and CDK6. It is administered through oral route as capsules.
Prelude Therapeutics overview
Prelude Therapeutics (Prelude) is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The company product pipeline includes PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor and PRT3645, a next-generation CDK4/6 inhibitor. Prelude others pipeline includes PRT3789 a first-in-class SMARCA2/BRM protein degraded. It also carries out clinical trials. The company serves throughout the US . Prelude is headquartered in Wilmington, Delaware, the United States.
For a complete picture of PRT-3645’s drug-specific PTSR and LoA scores, buy the report here.